Literature DB >> 24390153

Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.

Thomas Müller1, Siegfried Muhlack.   

Abstract

Oxidative stress is influenced by the thiol homeostasis, which regulates the redox milieu via glutathione. Components of glutathione metabolism are cysteine and cysteinyl-glycine. Both substrates decay following levodopa application or dopamine-related oxidative stress. Objective was to investigate the impact of an acute levodopa application with and without catechol-O-methyltransferase inhibitor on cysteine- and cysteinyl-glycine plasma levels. On two investigation days, 13 patients with Parkinson's disease took one retarded release 200-mg levodopa/50 mg carbidopa-containing tablet or one 150-mg levodopa/50-mg carbidopa/200-mg entacapone formulation under standardized conditions. Levodopa, 3-O-methyldopa, cysteine and cysteinyl-glycine were measured at baseline, 80 and 140 min following levodopa administration. Cysteine and cysteinyl-glycine similarly decreased, levodopa was nearly equal during both conditions. Entacapone lowered 3-O-methyldopa. Cysteine decay may be due to an elevated glutathione generation, which consumes cysteine. Cysteinyl-glycine decrease results from the alternative glutathione transformation to its oxidized form glutathione dissulfide after free radical scavenging.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390153     DOI: 10.1007/s00702-013-1155-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

Review 1.  Therapeutic role of coenzyme Q(10) in Parkinson's disease.

Authors:  Clifford W Shults
Journal:  Pharmacol Ther       Date:  2005-04-21       Impact factor: 12.310

Review 2.  Motor complications, levodopa metabolism and progression of Parkinson's disease.

Authors:  Thomas Müller
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-04-12       Impact factor: 4.481

3.  SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.

Authors:  H Przuntek; B Conrad; J Dichgans; P H Kraus; P Krauseneck; G Pergande; U Rinne; K Schimrigk; J Schnitker; H P Vogel
Journal:  Eur J Neurol       Date:  1999-03       Impact factor: 6.089

4.  Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  Mov Disord       Date:  2011-02-15       Impact factor: 10.338

5.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

6.  Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Authors:  Thomas Müller; Christoph Erdmann; Dirk Bremen; Wolfgang E Schmidt; Siegfried Muhlack; Dirk Woitalla; Oliver Goetze
Journal:  Clin Neuropharmacol       Date:  2006 Mar-Apr       Impact factor: 1.592

7.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states.

Authors:  George F G Allen; Yasmin Ullah; Iain P Hargreaves; John M Land; Simon J R Heales
Journal:  Neurochem Int       Date:  2012-12-19       Impact factor: 3.921

9.  Cysteine elevation in levodopa-treated patients with Parkinson's disease.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

10.  Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs.

Authors:  Constanze Jugel; Felicitas Ehlen; Birol Taskin; Frank Marzinzik; Thomas Müller; Fabian Klostermann
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more
  4 in total

Review 1.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.

Authors:  Thomas Müller; Isabel Trommer; Siegfried Muhlack; Bernhard K Mueller
Journal:  J Neural Transm (Vienna)       Date:  2016-02-15       Impact factor: 3.575

3.  How does resveratrol influence the genesis of some neurodegenerative diseases?

Authors:  Ester Tellone; Antonio Galtieri; Annamaria Russo; Silvana Ficarra
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

4.  Do we need a new levodopa?

Authors:  Thomas Müller
Journal:  Neural Regen Res       Date:  2016-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.